The United Kingdom and the United States have established a key bilateral deal that will preserve no duties on British drug products entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the public health system. This commitment guarantees that import taxes on these vital products will stay at nothing for a duration of three years.
This agreement follows earlier warnings to significantly raise import taxes on patented drug imports, with figures mentioned reaching double the cost.
"This deal with the Britain strengthens the worldwide climate for innovative medicines and establishes long-overdue balance to American-British drug exports," an announcement noted.
Commercial Importance
Drugs are one of the UK's most significant export categories to the US, which is clearly the primary market for large UK drugmakers.
Export figures reveal that in the 12 months leading up to last September, the UK sold drugs totaling over eleven billion pounds to the US. This value represented 17.4% of British export trade in that span.
"This deal secures employment, increases investment and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement includes several specific changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage manufacturers must return to the NHS to control costs will be capped at 15%. Last year, repayments exceeded 20%.
Recent Tensions
This agreement comes amid a ongoing tension between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by assertions that American consumers were paying significantly more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS must spend more on medicines, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
